Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Filter by Categories
Burning Issues
Case Report
Case Reports
Current Issue
Expert Commentary
Invited Editorial
Letter to the Editor
LetterTo Editor
MEDic LAWgic Series
Narrative Review
Original Article
Pictorial Update
Review Article
View/Download PDF

Translate this page into:

Letter to the Editor
72 (
); 110-111

Selecting antihyperglycemic agents with proven safety: A must in COVID-19 era

Department of Endocrinology, DR Samit Ghosal, 11 Shakespeare Sarani, Kolkata, West Bengal, India
Corresponding author: Samit Ghosal Department of Endocrinology, DR Samit Ghosal, 11 Shakespeare Sarani, Kolkata, West Bengal, India.
This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-Share Alike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.

How to cite this article: Ghosal S. Selecting antihyperglycemic agents with proven safety: A must in COVID-19 era. Indian J Med Sci 2020;72(2):110-1.

Dear Editor,

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has taken the medical fraternity off their comfort zone. On the one hand, we have to deal with the high rate of infectivity of the virus while, on the other hand, it burdens us with high mortality rate in those with comorbidities. Diabetes has been identified as an independent risk factor for worse prognosis in patients admitted with confirmed SARS-CoV-2.[1] It is our duty as physicians to ensure adequate glycemic control in patients with diabetes using all the resources available.

There is ample evidence of arrhythmias induced by SARS-CoV-2 infection per se with prolongation of QTc interval as one of the many mechanisms.[2] This issue is compounded by the use of medications with known predilection for QTc prolongation. There has been a push for the use of hydroxychloroquine as an antihyperglycemic agent proactively in patients with type 2 diabetes mellitus.[3] In addition, drugs like teneligliptin which have not passed the thorough QTc prolongation studies are prescribed in large numbers in India.[4]

I propose the use of antihyperglycemic agents with proven cardiorenal benefits from cardiovascular outcome trials (CVOTs) and proven safety derived from thorough QTc trials be considered preferentially in the management of type 2 diabetes. It would also be prudent to switch all patients receiving drugs without safety signals from dedicated CVOTs, for example, teneligliptin, hydroxychloroquine (as antihyperglycemic agent), and remogliflozin, to drugs with proven safety [Table 1].

Table 1:: Evidence-based choice of antihyperglycemic agents as outpatient management during SARS-CoV-2 pandemic.
Proven safety±anti-inflammatory property Safe Safety unproven
GLP1-RA Metformin Teneligliptin
DPP-4i SU Remogliflozin
Basal Insulin AGI Hydroxychloroquine
SGLT-2i (to be discontinued in active cases) Pioglitazone

GLP1-RA: Glucagon-like peptide receptor analog, DPP-4i: Dipeptidyl peptidase-4 inhibitor, SU: Sulfonylurea, AGI: Alpha-glucosidase inhibitor, SGLT: Sodium glucose cotransporter

There has been a flurry of publications implicating medications with the potential to upregulate angiotensin-converting enzyme (ACE2), which is known to be the human receptor for SARS- CoV-2 spike protein. Glucagon-like peptide receptor analog and dipeptidyl peptidase-4 inhibitors have been implicated as offenders.[5] However, the recent publications with the use of ACE inhibitors and ARBs have suggested otherwise.[6] The anti-inflammatory benefits of these agents overwhelm the potential harm associated with their ability to upregulating ACE2.

In light of all the recently available and evolving evidences, choosing antihyperglycemic agents prudently with stress on proven safety and anti-inflammatory properties rather than taking a myopic glucocentric view would reflect good clinical practice.

Declaration of patient consent

Patient’s consent not required as there are no patients in this study.

Financial support and sponsorship


Conflicts of interest

There are no conflicts of interest.


  1. , , , . Prevalence and impact of diabetes among people infected with SARS-CoV-2. J Endocrinol Invest. 2020;43:867-9.
    [CrossRef] [PubMed] [Google Scholar]
  2. , , , , . Cardiac and arrhythmic complications in patients with COVID-19. J Cardiovasc Electrophysiol. 2020;31:1003-8.
    [CrossRef] [PubMed] [Google Scholar]
  3. , , , , , , et al. Expert group consensus opinion: Role of anti-inflammatory agents in the management of Type-2 diabetes (T2D) J Assoc Physicians India. 2019;67:65-74.
    [Google Scholar]
  4. . Teneligliptin and “Thorough QTc Study”: Thorough enough? Diabetes Metab Syndr Obes. 2019;12:1141-2.
    [CrossRef] [PubMed] [Google Scholar]
  5. , . COVID-19, diabetes mellitus and ACE2: The conundrum. Diabetes Res Clin Pract. 2020;162:108132.
    [CrossRef] [PubMed] [Google Scholar]
  6. , , , . The Effect of Angiotensin Converting Enzyme Inhibitors and Angiotensin Receptor Blockers on Death and Severity of Disease in Patients with Coronavirus Disease 2019 (COVID-19): A Meta-Analysis. New Jersey: Authorea Inc; .
    [CrossRef] [Google Scholar]

Fulltext Views

PDF downloads
View/Download PDF
Download Citations
Show Sections